Antibody Variable Region Engineering for Improving Cancer Immunotherapy

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2022 Jul 13

PMID 35822503

Authors

Hantao Lou

Xuetao Cao

Affiliations

Soon will be listed here.

Abstract

The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted much attention. Variable region-retaining antibody fragments, such as antigen-binding fragment (Fab), single-chain variable fragment (scFv), bispecific antibody, and bi/trispecific cell engagers, are engineered with humanization, multivalent antibody construction, affinity optimization and antibody masking for targeting tumor cells and killer cells to improve antibody-based therapy potency, efficacy and specificity. In this review, we summarize the application of antibody variable region engineering and discuss the future direction of antibody engineering for improving cancer therapies.

Citing Articles

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.

Guo S, Xi X Biomark Res. 2025; 13(1):41.

PMID: 40069884 PMC: 11899093. DOI: 10.1186/s40364-025-00755-5.

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.

Peng X, Fang J, Lou C, Yang L, Shan S, Wang Z Acta Pharm Sin B. 2024; 14(8):3432-3456.

PMID: 39220871 PMC: 11365410. DOI: 10.1016/j.apsb.2024.05.010.

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

Wang Z, Zhou L, Wu X Oncol Res. 2024; 32(9):1479-1516.

PMID: 39220130 PMC: 11361912. DOI: 10.32604/or.2024.048564.

The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics.

Gezehagn Kussia G, Tessema T J Immunol Res. 2024; 2024:1804038.

PMID: 39156005 PMC: 11329312. DOI: 10.1155/2024/1804038.

Exploring treatment options in cancer: Tumor treatment strategies.

Liu B, Zhou H, Tan L, Siu K, Guan X Signal Transduct Target Ther. 2024; 9(1):175.

PMID: 39013849 PMC: 11252281. DOI: 10.1038/s41392-024-01856-7.

References

Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G . Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity. Cell. 2019; 177(7):1701-1713.e16. DOI: 10.1016/j.cell.2019.04.041. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J . Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006; 103(12):4586-91. PMC: 1450215. DOI: 10.1073/pnas.0505379103. View

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

Zhang J, Tanha J, Hirama T, Huan Khieu N, To R, Tong-Sevinc H . Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol. 2003; 335(1):49-56. DOI: 10.1016/j.jmb.2003.09.034. View

Loges S, Mazzone M, Hohensinner P, Carmeliet P . Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009; 15(3):167-70. DOI: 10.1016/j.ccr.2009.02.007. View

Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks J . Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007; 30(7):684-93. DOI: 10.1097/CJI.0b013e3180de5d90. View

Vosjan M, Vercammen J, Kolkman J, Stigter-van Walsum M, Revets H, van Dongen G . Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012; 11(4):1017-25. DOI: 10.1158/1535-7163.MCT-11-0891. View

10.

Mason D, Friedensohn S, Weber C, Jordi C, Wagner B, Meng S . Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat Biomed Eng. 2021; 5(6):600-612. DOI: 10.1038/s41551-021-00699-9. View

11.

Schlothauer T, Herter S, Koller C, Grau-Richards S, Steinhart V, Spick C . Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016; 29(10):457-466. DOI: 10.1093/protein/gzw040. View

12.

Duggan S . Caplacizumab: First Global Approval. Drugs. 2018; 78(15):1639-1642. PMC: 6280848. DOI: 10.1007/s40265-018-0989-0. View

13.

Schmidt A, Oberle N, Krammer P . Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012; 3:51. PMC: 3341960. DOI: 10.3389/fimmu.2012.00051. View

14.

Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W . Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020; 13(1):164. PMC: 7713173. DOI: 10.1186/s13045-020-01001-1. View

15.

Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K . Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020; 10(8):1194-1209. DOI: 10.1158/2159-8290.CD-20-0116. View

16.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

17.

Stieglmaier J, Benjamin J, Nagorsen D . Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. 2015; 15(8):1093-9. DOI: 10.1517/14712598.2015.1041373. View

18.

Harms B, Kearns J, Iadevaia S, Lugovskoy A . Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods. 2013; 65(1):95-104. DOI: 10.1016/j.ymeth.2013.07.017. View

19.

Schutt C, Mirandola L, Figueroa J, Nguyen D, Cordero J, Bumm K . The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma. Oncotarget. 2017; 8(59):100280-100287. PMC: 5725019. DOI: 10.18632/oncotarget.22213. View

20.

Fu J, Su X, Li Z, Deng L, Liu X, Feng X . HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021; 40(28):4625-4651. DOI: 10.1038/s41388-021-01863-w. View